Keyphrases
Psychiatric Disorders
100%
Selective Serotonin Reuptake Inhibitors
100%
Clinically Significant
14%
Depression Treatment
14%
5-hydroxytryptamine
14%
Tolerability
7%
Meta-analysis
7%
Comparative Efficacy
7%
Clinical Efficacy
7%
Plasma Concentration
7%
Clinical Conditions
7%
Therapeutic Advances
7%
Drug Development
7%
Increased Safety
7%
Antidepressants
7%
Mechanism of Action
7%
Safety Profile
7%
Sodium Channel
7%
Clinical Effect
7%
Physiological Processes
7%
Serotonin 5-HT
7%
Special Populations
7%
Social Anxiety
7%
Amines
7%
Elderly Patients
7%
Obsessive-compulsive Disorder
7%
Anorexia Nervosa
7%
Therapeutic Drug Monitoring
7%
Behavioral Therapy
7%
Biological Pathways
7%
Plethora
7%
Cytochrome P450 Enzymes
7%
Toxic Concentration
7%
Rational Drug Design
7%
Neuronal Uptake
7%
Therapeutic Mechanism
7%
Psychopharmacology
7%
Noradrenergic Neurons
7%
Therapeutic Action
7%
Nutritional Intervention
7%
Inhibitory Properties
7%
Neuroreceptors
7%
Biological Substrates
7%
Serotonergic Neurons
7%
CYP2C19
7%
Cytochrome P450 2D6 (CYP2D6)
7%
Biological Receptors
7%
Reduced Likelihood
7%
Sparteine
7%
Mephenytoin
7%
Social Anxiety Disorder
7%
First-line Drugs
7%
5-HT Receptor Subtypes
7%
Liver Impairment
7%
5-HT System
7%
Neuropsychopharmacology
7%
Adverse Drug-drug Interaction
7%
Poor Metabolizer
7%
Pharmacokinetic Drug Interactions
7%
Substrate Receptors
7%
Kidney Impairment
7%
Intended Outcome
7%
Pharmacology, Toxicology and Pharmaceutical Science
Selective Serotonin Reuptake Inhibitor
100%
Serotonin
42%
Drug Development
14%
Drug-Drug Interaction
14%
Psychotropic Agent
14%
Psychopharmacology
14%
Side Effect
14%
Tolerability
7%
Antidepressant
7%
Receptor
7%
Cytochrome P450
7%
Obsessive Compulsive Disorder
7%
CYP2D6
7%
Receptor Subtype
7%
Anorexia Nervosa
7%
CYP2C19
7%
Mephenytoin
7%
Social Phobia
7%
Sodium Channel
7%
Combination Therapy
7%
Therapeutic Drug Monitoring
7%
Sparteine
7%
Pharmacokinetics
7%